Clinical Trial Update: Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating peginterferon alfa-2a and ribavirin with or without telaprevir for genotype 1 Hepatitis C (IL28B CC polymorphism) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Incivek (telaprevir)
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: University of Vermont | Conditions: Hepatitis C | Phase 4 | Status: WITHDRAWN